Correction to: ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation.

Correction to: Cellular & Molecular Biology Letters (2022) 27:23 https://doi.org/10.1186/s11658-022-00327-7

Following publication of the original article [1], the authors identified a few errors in panel A of Fig. 4. Two western blot images from panel B (Bcl-xL and Actin) were duplicated by mistake into panel A in place of the western blots for MDM2 and the Actin controls for both MDM2 and p53. The correct Fig. 4 is given in this correction article.

Fig. 4

ROR2 regulates the expression of MDM2, p53, and Bcl2-family proteins through the hyperactivation of ERK. A PLX inhibited MDM2 levels and increased p53 in A375-ROR2 cells. The cells were treated with 10 µM PLX for the indicated time. The graphs show the mean ± SD of each protein’s levels normalized to the corresponding loading control and expressed as the fold change (FC) relative to untreated cells. B Bcl2 proteins are regulated by the MAPK/ERK pathway in A375-ROR2 cells. The cells were treated with 10 µM PLX for the indicated times. The graphs show the mean ± SD of Bcl-xL, Mcl-1, and Bax normalized to the corresponding loading control and expressed as the fold change (FC) relative to untreated cells. Statistical signifcance was tested by a one-tailed Student’s t-test or ANOVA as appropriate (n = 3). ***p < 0.0001, n.s. not significant